Preventing Staphylococcus aureus infection in the renal unit

QJM: An International Journal of Medicine

Volumn 95, Issue 6, 2002, Pages 405-410

  Peacock, S J ^a,b   Mandal, S ^a   Bowler, I C J W ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; POVIDONE IODINE; PSEUDOMONIC ACID;

ARTICLE; ASEPSIS; BACTERIAL COLONIZATION; BACTERIUM CARRIER; CATHETER; CATHETER INFECTION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEMODIALYSIS; HUMAN; INFECTION CONTROL; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

EID: 0036075506     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/95.6.405     Document Type: Article

References (54)

1. Staphylococcus aureus and other bacteremias in hemodialysis patients: Antibiotic therapy and surgical removal of access site
2. Outcome and complications of temporary haemodialysis catheters
3. Exit-site and tunnel infections in continuous ambulatory peritoneal dialysis patients
4. Risk factors for tunnel infections in continuous peritoneal dialysis
5. Analysis of microbiological trends in peritoneal dialysis-related peritonitis from 1991 to 1998
6. Nasal carriage of Staphylococcus aureus: Epidemiology, underlying mechanisms, and associated risks
7. Nasal carriage and peritonitis by Staphylococcus aureus in patients on continuous ambulatory peritoneal dialysis: A prospective study
8. Staphylococcus aureus carriage and infections among patients in four haemo- and peritoneal-dialysis centres in Denmark
9. Treatment of Staphylococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: Long-term results
10. Staphylococcus aureus carriage in adult peritoneal dialysis patients and their spouses
11. Staphylococcus aureus carriage rate of patients receiving long-term hemodialysis
12. Elimination of nasal carriage of Staphylococcus aureus in hemodialysis patients
13. Optimizing screening procedures for Staphylococccus aureus nasal carriage in patients on haemodialysis
14. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis
15. Staphylococcal nasal carriage and subsequent infection in peritoneal dialysis patients
16. Staphylococcus aureus nasal carriage, exit-site infection and catheter loss in patients treated with continuous ambulatory peritoneal dialysis (CAPD)
17. Staphylococcus aureus skin carriage and development of peritonitis in patients on continuous ambulatory peritoneal dialysis
18. Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis
19. Staphylococcus aureus peritonitis is associated with Staphylococcus aureus nasal carriage in peritoneal dialysis patients
20. Risk factors for peritoneal dialysis-related infections
21. Staphylococcus aureus CAPD-related infections are associated with nasal carriage
22. Natural history of Staphylococcus aureus nasal carriage and its relationship to exit-site infection
23. Staphylococcus aureus colonization and infection in patients on continuous ambulatory peritoneal dialysis
24. Epidemiology of Staphylococcus aureus infections in patients on hemodialysis
25. The effect of hemodialysis on neutrophil chemotactic responsiveness
26. Impaired phagocytic activity of neutrophils in patients receiving haemodialysis: The critical role of iron overload
27. Immune system to uremia
28. T cell subsets and cellular immunity in end-stage renal disease
29. Risk factors associated with permanent access-site infections in chronic hemodialysis patients
30. EPIBACDIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients
31. Active intervention dramatically reduces CAPD-associated infection
32. Peritonitis prevention in CAPD: To mask or not?
33. Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion
34. Preoperative vancomycin prophylaxis decreases incidence of postoperative hemodialysis vascular access infections
35. Exit-site care and exit-site infection in continuous ambulatory peritoneal dialysis (CAPD): Results of a randomized multicenter trial
36. The efficacy of exit site povidone-iodine ointment in the prevention of early peritoneal dialysis-related infections
37. The use of povidone iodine in exit site care for patients undergoing continuous peritoneal dialysis (CAPD)
38. Prevention of hemodialysis subclavian vein catheter infections by topical povidone-iodine
39. Prevention of haemodialysis and peritoneal dialysis catheter related infection by topical povidone-iodine
40. Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment
41. The influence of calcium mupirocin nasal ointment on the incidence of Staphylococcus aureus infections in haemodialysis patients
42. Efficacy of mupirocin nasal ointment in eradicating Staphylococcus aureus nasal carriage in chronic haemodialysis patients
43. The efficacy of mupirocin ointment and chlorhexidine body scrubs in the eradication of nasal carriage of Staphylococcus aureus among patients undergoing long-term hemodialysis
44. Nasal mupirocin ointment decreases the incidence of Staphylococcus aureus bacteraemias in haemodialysis patients
45. Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis
46. Long-term evaluation of chemoprophylaxis of S. aureus bacteraemia in haemodialysis by nasal mupirocin
47. Clinical and economic effects of mupirocin calcium on preventing Staphylococcus aureus infection in hemodialysis patients: A decision analysis
48. Cost-effectiveness of prophylactic nasal mupirocin in patients undergoing peritoneal dialysis based on a randomized, placebo-controlled trial
49. Outcome and clinical implications of a surveillance and treatment program for Staphylococcus aureus nasal carriage in peritoneal dialysis patients
50. Staphylococcus aureus prophylaxis in hemodialysis patients using central venous catheter: Effect of mupirocin ointment
51. Staphylococcal peritonitis in continuous ambulatory peritoneal dialysis: Colonization with identical strains at exit site, nose, and hands
52. Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site
53. A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: Mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin
54. Guidelines for the management of intravascular catheter-related infections